The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
Abstract
PURPOSE: Recipients of allogeneic bone marrow transplants (BMTs) who have relapsed may attain complete remissions when treated with transfusions of leukocytes obtained from the original bone marrow donor. We performed a retrospective study to characterize better this new treatment modality. PATIENTS AND METHODS: We surveyed 25 North American BMT programs regarding their use of donor leukocyte infusions (DLI). Detailed forms were used to gather data regarding the original BMT, relapse, DLI, response to DLI, complications of DLI, and long-term follow-up evaluation. Reports of 140 patients were thus available for analysis. RESULTS: Complete responses were observed in 60% (95% confidence interval [CI], 51.9% to 68.1%) of chronic myelogenous leukemia (CML) patients who received DLI and did not receive pre-DLI chemotherapy; response rates were higher in patients with cytogenetic and chronic-phase relapse (75.7%; 95% CI, 68.2% to 83.2%) than in patients with accelerated-phase (33.3%; 95% CI, 19.7% to 46.9%) or blastic-phase (16.7%; 95% CI, 1.9% to 31.9%) relapse. The actuarial probability of remaining in complete remission at 2 years was 89.6%. Complete remission rates in acute myelogenous leukemia (AML) (n = 39) and acute lymphocytic leukemia (ALL) (n = 11) patients who had not received pre-DLI chemotherapy were 15.4% (95% CI, 9.6% to 21.2%) and 18.2% (95% CI, 6.6% to 29.8%), respectively. Complete remissions were also observed in two of four assessable myeloma patients and two of five assessable myelodysplasia patients. Complications of DLI included acute graft-versus-host disease (GVHD) (60%; 95% CI, 51.4% to 68.6%), chronic GVHD (60.7%; 95% CI, 50.3% to 71.1%), and pancytopenia (18.6%; 95% CI, 12.2% to 25.0%). Pre-DLI characteristics predictive of complete response in CML patients were post-BMT chronic GVHD, pre-DLI disease status of chronic phase, and time interval between BMT to DLI less than 2 years. Acute and chronic GVHD post-DLI were highly correlated with disease response (P < .00001). CONCLUSION: DLI results in complete remissions in a high percentage of patients with relapsed chronic-phase CML. Complete remissions are observed less frequently in patients with advanced CML and acute leukemia. GVHD and pancytopenia occur commonly; GVHD is highly correlated with response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
GLUCKSBERG, H., STORB, R., FEFER, A., BUCKNER, C. D., NEIMAN, P. E., CLIFT, R. A., LERNER, K. G., & THOMAS, E. D. (1974) · Transplantation · doi:10.1097/00007890-197410000-00001 · Cited by 3,694
Graft-versus-leukemia reactions after bone marrow transplantation
Horowitz, M., Gale, R., Sondel, P., Goldman, J., Kersey, J., Kolb, H., Rimm, A., Ringden, O., Rozman, C., & Speck, B. (1990) · Blood · doi:10.1182/blood.v75.3.555.555 · Cited by 2,774
Chronic graft-versus-host syndrome in man
Shulman, H. M., Sullivan, K. M., Weiden, P. L., McDonald, G. B., Striker, G. E., Sale, G. E., Hackman, R., Tsoi, M.-S., Storb, R., & Donnall Thomas, E. (1980) · The American Journal of Medicine · doi:10.1016/0002-9343(80)90380-0 · Cited by 2,406
Kolb, H., Schattenberg, A., Goldman, J., Hertenstein, B., Jacobsen, N., Arcese, W., Ljungman, P., Ferrant, A., Verdonck, L., & Niederwieser, D. (1995) · Blood · doi:10.1182/blood.v86.5.2041.bloodjournal8652041 · Cited by 1,934
Kolb, H., Mittermuller, J., Clemm, C., Holler, E., Ledderose, G., Brehm, G., Heim, M., & Wilmanns, W. (1990) · Blood · doi:10.1182/blood.v76.12.2462.2462 · Cited by 1,528
Weiden, P. L., Sullivan, K. M., Flournoy, N., Storb, R., Thomas, E. D., & The Seattle Marrow Transplant Team (1981) · New England Journal of Medicine · doi:10.1056/nejm198106183042507 · Cited by 1,081
Mackinnon, S., Papadopoulos, E., Carabasi, M., Reich, L., Collins, N., Boulad, F., Castro-Malaspina, H., Childs, B., Gillio, A., & Kernan, N. (1995) · Blood · doi:10.1182/blood.v86.4.1261.bloodjournal8641261 · Cited by 722
Graft-versus-myeloma effect: proof of principle
Tricot, G., Vesole, D., Jagannath, S., Hilton, J., Munshi, N., & Barlogie, B. (1996) · Blood · doi:10.1182/blood.v87.3.1196.bloodjournal8731196 · Cited by 543
Drobyski, W. R., KEEVER, C. A., Roth, M. S., Koethe, S., Hanson, G. A., McFadden, P. W., Gottschall, J., Ash, R., van Tuinen, P., & Horowitz, M. (1993) · Blood · doi:10.1182/blood.v82.8.2310.2310 · Cited by 346
Self-citationvan Rhee, F., Lin, F., Cullis, J., Spencer, A. G., Cross, N. C. P., Chase, A., Garicochea, B., Bungey, J., Barrett, J. A., & Goldman, J. M. (1994) · Blood · doi:10.1182/blood.v83.11.3377.3377 · Cited by 341
Giralt, S. A., Hester, J. P., Huh, Y. O., Hirsch‐Ginsberg, C., Rondón, G., Seong, D., Lee, M., Gajewski, J., van Besien, K., & Khouri, I. F. (1995) · Blood · doi:10.1182/blood.v86.11.4337.bloodjournal86114337 · Cited by 318
Self-citationALLOGENEIC BONE-MARROW TRANSPLANTATION FOR CHRONIC MYELOGENOUS LEUKAEMIA
Speck, B., Bortin, M., Champlin, R., Goldman, J., Herzig, R., Mcglave, P., Messner, H., Weiner, R., & Rimm, A. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92179-2 · Cited by 259
Self-citationTiberghien, P., Reynolds, C., Keller, J., Spence, S., Deschaseaux, M., Certoux, J., Contassot, E., Murphy, W., Lyons, R., & Chiang, Y. (1994) · Blood · doi:10.1182/blood.v84.4.1333.1333 · Cited by 214
Faber, L. M., van Luxemburg-Heijs, S. A. P., Willemze, R., & Falkenburg, J. H. F. (1992) · The Journal of Experimental Medicine · doi:10.1084/jem.176.5.1283 · Cited by 136
Higano, C. S., Brixey, M., Bryant, E. M., et al. (1990) · PubMed · Cited by 93
Upadhyaya, G., Guba, S. C., Sih, S. A., Feinberg, A. P., Talpaz, M., Kantarjian, H. M., Deisseroth, A., & Emerson, S. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115543 · Cited by 84
Sosman, J. A., Oettel, K., Smith, S. D., Hank, J. A., Fisch, P., & Pm, S. (1990) · Blood · doi:10.1182/blood.v75.10.2005.2005 · Cited by 68
Cited by
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Self-citationDöhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Cividalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., et al. (1998) · Blood · doi:10.1182/blood.v91.3.756 · Cited by 2,071
McSweeney, P. A., Niederwieser, D., Shizuru, J. A., Sandmaier, B. M., Molina, A. J., Maloney, D. G., Chauncey, T. R., Gooley, T. A., Hegenbart, U., Nash, R. A., et al. (2001) · Blood · doi:10.1182/blood.v97.11.3390 · Cited by 1,389
The Biology of Chronic Myeloid Leukemia
Faderl, S., Talpaz, M., Estrov, Z., O'Brien, S., Kurzrock, R., & Kantarjian, H. M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907153410306 · Cited by 1,302
Metadata
- Authors
- Collins, R. H., Shpilberg, O., Drobyski, W. R., Porter, D. L., Giralt, S., Champlin, R., Goodman, S. A., Wolff, S. N., Hu, W., Verfaillie, C., List, A., Dalton, W., Ognoskie, N., Chetrit, A., Antin, J. H., & Nemunaitis, J.
- Venue
- Journal of Clinical Oncology
- Published
- 1997-02
- Volume
- 15
- Issue
- 2
- Pages
- 433-444
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1873141201
- Cited by
- 1,237
- References
- 18
- FWCI
- 35.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.